[{"id":"e9a2422f-d4f9-4a61-a157-fe8158579752","acronym":"","url":"https://clinicaltrials.gov/study/NCT05223816","created_at":"2022-02-05T18:29:35.392Z","updated_at":"2024-07-02T16:35:15.881Z","phase":"Phase 2","brief_title":"An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma","source_id_and_acronym":"NCT05223816","lead_sponsor":"Virogin Biotech Canada Ltd","biomarkers":" MSI • IDH1","pipe":" | ","alterations":" MSI-H/dMMR • IDH1 mutation","tags":["MSI • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 01/24/2024","start_date":" 01/24/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-07"},{"id":"5f5b7d90-82b7-4d29-a76d-1af846240ca3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008925","created_at":"2023-08-24T16:11:24.123Z","updated_at":"2024-07-02T16:35:39.126Z","phase":"Phase 1/2","brief_title":"Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer","source_id_and_acronym":"NCT06008925","lead_sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","biomarkers":" PD-L1 • CD8 • IL6 • NCAM1","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • IL6 • NCAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-08-24"},{"id":"d2fb6681-a16d-488c-b535-67b0e2be61b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05162118","created_at":"2021-12-17T17:31:15.748Z","updated_at":"2024-07-02T16:36:15.755Z","phase":"Phase 1/2","brief_title":"Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer","source_id_and_acronym":"NCT05162118","lead_sponsor":"Zhejiang University","biomarkers":" CD8 • PD-1 • IFNG • IL6 • TNFA • CD4 • NCAM1 • CA 19-9","pipe":"","alterations":" ","tags":["CD8 • PD-1 • IFNG • IL6 • TNFA • CD4 • NCAM1 • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/08/2022","start_date":" 03/08/2022","primary_txt":" Primary completion: 03/22/2025","primary_completion_date":" 03/22/2025","study_txt":" Completion: 12/22/2025","study_completion_date":" 12/22/2025","last_update_posted":"2022-03-09"},{"id":"ae8410e8-deea-4756-9774-18fb45fe7247","acronym":"","url":"https://clinicaltrials.gov/study/NCT04758897","created_at":"2021-02-17T14:01:03.261Z","updated_at":"2024-07-02T16:36:31.185Z","phase":"Phase 1","brief_title":"Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT04758897","lead_sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","biomarkers":" PD-L1 • CD8 • PD-1 • CD4 • IL15 • NECTIN2","pipe":"","alterations":" ","tags":["PD-L1 • CD8 • PD-1 • CD4 • IL15 • NECTIN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 03/14/2022","primary_completion_date":" 03/14/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2021-04-27"},{"id":"63367a2e-68e2-4d92-bf7f-8520dd8d4a6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04806464","created_at":"2021-03-19T15:59:01.717Z","updated_at":"2024-07-02T16:36:31.305Z","phase":"Phase 1","brief_title":"Clinical Study of VG161 in Subjects With Advanced Primary Liver Cancer","source_id_and_acronym":"NCT04806464","lead_sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","biomarkers":" PD-L1 • PD-1 • CD4 • IL15","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • CD4 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VG161"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/16/2021","start_date":" 03/16/2021","primary_txt":" Primary completion: 03/21/2022","primary_completion_date":" 03/21/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2021-04-23"}]